The combination of plasma p-tau181 and YKL-40 had the best performance to differentiate DLB patients from AD-MCI (AUC = 0.86, ∂AIC > 4 versus all biomarkers model [AUC = 0.88] and p-tau181 alone [AUC = 0.80]), with the best trade-off between the goodness of fit and parsimony. This evidence concerns the gene CHI3L1 and Lewy body dementia.